The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2022

Filed:

Jan. 25, 2019
Applicant:

Beijing Scitech-mq Pharmaceuticals Limited, Beijing, CN;

Inventors:

Qiang Zhang, Beijing, CN;

Shannan Yu, Beijing, CN;

Zhongxiang Wang, Beijing, CN;

Shouye Feng, Beijing, CN;

Yansheng Liu, Beijing, CN;

Xingfu Li, Beijing, CN;

Hongbo Zhang, Beijing, CN;

Leifu Yang, Beijing, CN;

Hailong Yang, Beijing, CN;

Likai Zhou, Beijing, CN;

Nanqiao Zheng, Beijing, CN;

Chenming Hu, Beijing, CN;

Zhanqiang Xu, Beijing, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 491/056 (2006.01); A61K 31/4741 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/54 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 491/056 (2013.01); A61K 31/4741 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 31/54 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.


Find Patent Forward Citations

Loading…